LENZ Therapeutics reports FY2024 net loss $49.8M; LNZ100 PDUFA set for Aug 8, 2025

LENZ Therapeutics, Inc.

FDA accepted NDA for LNZ100 (presbyopia); PDUFA target action date Aug 8, 2025; no advisory committee planned.
Cash, cash equivalents & marketable securities $209.1M; cash runway expected to post-launch positive operating cash flow.
FY2024 net loss $49.8M ($2.34/share) vs FY2023 net loss $70.0M ($35.71/share).
R&D expenses fell to $29.8M in FY2024 from $59.5M in FY2023 as Phase 3 CLARITY study concluded.
SG&A expenses rose to $28.8M in FY2024 from $12.9M in FY2023 due to pre-commercial buildout for potential LNZ100 launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.